Global Personalized Medicines Strategic Market Report 2023: Market to Surpass $740 Billion by 2030 - Genomics to Dictate Advancement of Personalized Medicines

News provided by

Feb 16, 2023, 22:40 ET

DUBLIN, Feb. 16, 2023 /PRNewswire/ -- The "Personalized Medicines: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Global Personalized Medicines Market to Reach $740.3 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Personalized Medicines estimated at US$508 Billion in the year 2022, is projected to reach a revised size of US$740.3 Billion by 2030, growing at a CAGR of 4.8% over the analysis period 2022-2030.

Personalized Nutrition & Wellness, one of the segments analyzed in the report, is projected to record a 4.6% CAGR and reach US$437.9 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Personalized Medical Care segment is readjusted to a revised 5.2% CAGR for the next 8-year period.

The U.S. Market is Estimated at $148.6 Billion, While China is Forecast to Grow at 4.5% CAGR

The Personalized Medicines market in the U.S. is estimated at US$148.6 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$130.3 Billion by the year 2030 trailing a CAGR of 4.5% over the analysis period 2022 to 2030.

Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.3% and 4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR.

Looking Ahead to 2023

Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced.

Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

What`s New?

Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
Global competitiveness and key competitor percentage market shares
Market presence across multiple geographies - Strong/Active/Niche/Trivial
Online interactive peer-to-peer collaborative bespoke updates
Access to digital archives and Research Platform
Complimentary updates for one year

Key Topics Covered:

MARKET OVERVIEW

Influencer Market Insights
World Market Trajectories
Access to Valuable Genetic Information Ushers Transformation in Medicine
Recent Market Activity
Market Outlook
Adoption of Personalized Medicines - A Peek into Developed and Developing Economies
Increasing Market Availability of Personalized Medicines
Select Key Approved Personalized Medicines and Associated Biomarkers by Therapeutic Area
Constraints in Traditional Approach to Treatment Creates Need and Demand for Personalized Medicine
Economics of Personalized Medicine
Is Emergence of Personalized Medicine Signaling the End of Blockbusters?
Personalized Medicines - Global Key Competitors Percentage Market Share in 2022
Impact of Covid-19 and a Looming Global Recession

MARKET TRENDS & DRIVERS

Growth Drivers in a Gist
Key Market Restraints
Increasing Incidence and Prevalence of CDDs: A Major Growth Driver
Oncology - A Major Application Market
Diagnosed Cases of Cancer on the Rise
World Cancer Statistics: Incidence and Mortality Data
Growing Cancer Cases in Developing Countries Bodes Well for the Personalized Medicine Market
Growing Importance of Personalized Drugs for Cancer Treatment
Ballooning Global Population Offers Significant Growth Opportunities
Aging Global Population Drives Personalized Medicines
Increasing Healthcare Spending in Emerging Markets
Changing Patients' Trends Drive Personalized Medicine
Technological Advancements and Consumer Push to Drive Personalized Medicine
Minimizing Adverse Events - A Major Benefit of Personalized Medicines
Personalized Medicines Brings Disease Prevention Closer to Reality
Ability to Manage Healthcare Costs Piques Industry and Government Alike
Potential to Uncover Additional Prospective Targets - A Major Benefit in Pursuit
Elimination of Invasive Tests Attracts Patients and Doctors towards Molecular Test-based Personalized Medicines
Genomics to Dictate Advancement of Personalized Medicines
Companion Diagnostics Drive Personalized Medicine
Biomarkers as Companion Diagnostics
Personalized Medicines Help Reducing R&D Costs
Personalized Medicine - A Corporate Growth Strategy
Development Pipeline Reveals Promising Picture for Personalized Medicine
Advancements in Biomedical Imaging to Enhance Personalized Medicines
Increasing Use of Personalized Medicines Drives Genetic Testing
Genetic Testing: The Rapidly Growing Segment of Molecular Diagnostics Market
Next-Generation Sequencing - A Giant Leap in Genome Sequencing
Single Nucleotide Polymorphism (SNP) - Making Advancements in Personalized Medicine
Personalized Medicine Goes Beyond DNA Analysis
Combination Approaches May Mark Future Endeavors
Need for New Designs in Clinical Trials Emerges in Therapies for Rare Cancers
Immunotherapy for Cancers - A Potential Breakthrough in the Sector
Personalized Medicine Industry - Inundated with Data
Advanced Computing Technologies - The Need of The Hour to Analyze Large Data
Artificial Intelligence Revolutionizing Personalized Medicine
Challenges Aplenty for Precision Medicine
Lack of Clinically Useful Diagnostic Tests - Growth Dampener
Pricing and Value Dilemma Haunts Personalized Medicines
Bedside Biopharmaceutical Production to Dramatically Reduce Cost of Personalized Medicine

FOCUS ON SELECT PLAYERS (Total 87 Featured)

Abbott Molecular, Inc. (USA)
Beckman Coulter Genomics (USA)
bioMerieux SA (France)
Bristol-Myers Squibb Company (USA)
Dako Denmark A/S (Denmark)
F. Hoffmann-La Roche Ltd. (Switzerland)
GlaxoSmithKline plc. (UK)
Hologic, Inc. (USA)
Lab 21 Limited (UK)
Macrogen, Inc. (Korea)
NeoGenomics Laboratories, Inc. (USA)
Novartis AG (Switzerland)
QIAGEN NV (The Netherlands)
Rosetta Genomics Ltd (Israel)
Thermo Fisher Scientific Inc. (USA)

For more information about this report visit https://www.researchandmarkets.com/r/xco4y7

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets